natgillin/translations-raw huggingface dataset:
Submission of the final clinical study report on a Post-Authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients with Anoro compared with tiotropium (study 201038), according to a protocol agreed by the PRAC.
Podnijeti završno izvješće o kliničkom ispitivanju za opservacijsko kohortno ispitivanje sigurnosti primjene nakon dobivanja odobrenja, koje ima za cilj kvantificirati incidenciju i usporediti sigurnost s obzirom na odabrane
Submission of the final clinical study report on a Post-Authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients with Incruse compared with tiotropium (study 201038), according to a protocol agreed by the PRAC.
Podnijeti završno izvješće o kliničkom ispitivanju za opservacijsko kohortno ispitivanje sigurnosti primjene nakon dobivanja odobrenja, koje ima za cilj kvantificirati incidenciju i usporediti sigurnost s obzirom na odabrane kardiovaskularne i cerebrovaskularne događaje u bolesnika s KOPB-om kod primjene lijeka Incruse u usporedbi s tiotropijem (ispitivanje: 201038), prema protokolu dogovorenom od strane Povjerenstva za ocjenu rizika na području farmakovigilancije.
Submission of the final clinical study report on a Post-Authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients with Laventair compared with tiotropium (study 201038), according to a protocol agreed by the PRAC.
Podnijeti završno izvješće o kliničkom ispitivanju za opservacijsko kohortno ispitivanje sigurnosti primjene nakon dobivanja odobrenja, koje ima za cilj kvantificirati incidenciju i usporediti sigurnost s obzirom na odabrane
Submission of the results of the agreed drug utilisation study (DUS) and post- authorisation safety study (PASS) for aclidinium bromide to evaluate the overall mortality and the proposed cardiovascular safety endpoints (with an additional endpoint of cardiac arrhythmia) among patients with COPD using aclidinium/formoterol, according to a protocol agreed by the PRAC.
Podnošenje rezultata dogovorenog ispitivanja potrošnje lijeka (Drug Utilisation Study, DUS) i ispitivanja sigurnosti primjene lijeka nakon stavljanja lijeka u promet (Post- Authorisation Safety Study, PASS) za aklidinijev bromid za procjenu ukupne smrtnosti i predloženih mjera ishoda kardiovaskularne sigurnosti (uz dodatnu mjeru ishoda, srčanu aritmiju) među bolesnicima s KOPB-om koji koriste aklidinij/formoterol, sukladno planu ispitivanja koji je usuglašen s PRAC-om.
Submission of the results of the biomarker programme encompassing the EFC10262, EFC10668 and EFC11338 studies
Predaja rezultata programa biomarkera koji obuhvaća ispitivanja EFC10262, EFC10668 i EFC11338
Submission of yearly updates of study 1112 results for progression and death - to be provided until maturity in the ibrutinib arm, e.g.
Predaja najnovijih godišnjih rezultata ispitivanja 1112, podataka za progresiju i smrt – potrebno je dostaviti do zrelosti u ibrutinib skupini, npr.
submit mature overall survival data for study JO25567 (due date: Q2 2018)
odobrenja mora dostaviti zrele podatke o ukupnom preživljenju iz ispitivanja
Submit the final study report from the MARIANNE study once available
Podnijeti završno izvješće o ispitivanju MARIANNE, kada bude dostupno
Submit the final study report from the TH3RESA study once available
Podnijeti završno izvješće o ispitivanju TH3RESA, kada bude dostupno
submitted with each
podnositi sa svakim
Submucosal vaccination of 0.2 ml of reconstituted product.
Submukozno cijepljenje s 0,2 ml rekonstituiranog proizvoda.
Suboxone
ubokson
Suboxone 16 mg/4 mg sublingual tablets
Suboxone 16 mg/4 mg sublingvalne tablete
Suboxone 16 mg/4 mg sublingual tablets buprenorphine / naloxone
Suboxone 16 mg/4 mg sublingvalne tablete buprenorfin/nalokson
Suboxone 16 mg/4 mg sublingual tablets buprenorphine/naloxone
Suboxone 16 mg/4 mg sublingvalne tablete buprenorfin/nalokson
Suboxone 2 mg/0.5 mg sublingual tablets
Suboxone 2 mg/0,5 mg sublingvalne tablete
Suboxone 2 mg/0.5 mg sublingual tablets buprenorphine / naloxone
Suboxone 2 mg/0,5 mg sublingvalne tablete buprenorfin/nalokson
Suboxone 2 mg/0.5 mg sublingual tablets buprenorphine/naloxone
Suboxone 2 mg/0,5 mg sublingvalne tablete buprenorfin/nalokson
Suboxone 8 mg/2 mg sublingual tablets
Suboxone 8 mg/2 mg sublingvalne tablete
Suboxone 8 mg/2 mg sublingual tablets buprenorphine / naloxone
Suboxone 8 mg/2 mg sublingvalne tablete buprenorfin/nalokson
Suboxone 8 mg/2 mg sublingual tablets buprenorphine/naloxone
Suboxone 8 mg/2 mg sublingvalne tablete buprenorfin/nalokson
Suboxone is used to treat dependence on opioid (narcotic) drugs such as heroin or morphine in drug addicts who have agreed to be treated for their addiction.
Suboxone se koristi za liječenje ovisnosti o opioidima (narkoticima) kao što su heroin ili morfij kod ovisnika o drogama koji su pristali na liječenje ovisnosti.
Subsequent 2 to 3 Infusions (ml/hour)
Sljedeće 2-3 infuzije (ml/sat)
Subsequent 2-3 Infusions (ml/hour)
Sljedeće 2-3 infuzije (ml/sat)
Subsequent administrations:
Sljedeće primjene:
Subsequent cycles: 1,000 mg on day 1 every 28 days) in combination with chlorambucil (10 mg/m2 orally on days 1-7 every 28 days) or chlorambucil alone (10 mg/m2 orally on days 1-7 every 28 days).
1. dana svakih 28 dana) u kombinaciji s klorambucilom (10 mg/m2 peroralno od 1. do 7. dana svakih 28 dana) ili samo klorambucil (10 mg/m2 peroralno od 1. do 7. dana svakih 28 dana).
Subsequent dilution to 200 µg/mL
Sljedeće razrjeđivanje na 200 µg/mL
Subsequent dose
Sljedeća doza
Subsequent dose adjustments should be based on individual safety and tolerability (see section 5.2).
Kasnije prilagodbe doze ovise o individualnoj sigurnosti i podnošljivosti (vidjeti dio 5.2).
Subsequent dose Days 8 - 28
Sljedeća doza Dani 8 - 28
Subsequent doses (single administration or two doses of 10 mg given 12 hours apart) should be administered only on haemodialysis days following each dialysis session.
Naknadne doze (jednokratna primjena ili dvije doze od 10 mg dane u razmaku od 12 sati) treba primjenjivati samo u dane hemodijalize i to nakon svakog postupka dijalize.
Subsequent doses of vaccine should be given according to the locally recommended vaccination schedule.
Sljedeće doze cjepiva treba dati u skladu s lokalnim preporučenim kalendarom cijepljenja.
Subsequent doses: Topotecan should not be re-administered unless the neutrophil count is more than or equal to 1.5 x 109/l, the platelet count is more than or equal to 100 x 109/l, and the haemoglobin level is more than or equal to 9g/dl (after transfusion if necessary).
Daljnje doze: Topotekan se ne smije ponovno primijeniti ukoliko broj neutrofila nije veći ili jednak 1,5x109/l, broj trombocita veći ili jednak 100x109/l i razina hemoglobina veća ili jednaka 9 g/dl (nakon transfuzije ukoliko je potrebna).
Subsequent doses: Topotecan should not be re-administered unless the neutrophil count is ≥ 1 x 109/l, the platelet count is ≥ 100 x 109/l, and the haemoglobin level is ≥ 9 g/dl (after transfusion if necessary).
Daljnje doze: Topotekan se ne smije ponovno primijeniti ukoliko broj neutrofila nije ≥ 1 x 109/l, broj trombocita ≥ 100 x 109/l i razina hemoglobina ≥ 9 g/dl (nakon transfuzije ukoliko je potrebna).
Subsequent flea prevention should be with a different product containing a single active substance.
Naknadna prevencija od buha mora se provoditi drugačijim proizvodom koji sadrži jednu djelatnu tvar.
Subsequent implantations should be based on the increase in testis size and/or increase in plasma testosterone concentrations as well as return to sexual activity.
Razlog za ponovnu implantaciju je povećanje veličine testisa i /ili povišena koncentracija testosterona i povratak seksualne aktivnosti.
Subsequent increases to 4.5 mg and then mg twice a day should also be based on good tolerability of the current dose and may be considered after a minimum of two weeks of treatment at that dose level.
Daljnja se povećanja na dozu od 4,5 mg, a zatim na 6 mg dva puta dnevno, trebaju također temeljiti na dobroj podnošljivosti trenutne doze, a mogu se razmatrati nakon najmanje dva tjedna liječenja s tom dozom.
Subsequent infusionsb
Sljedeće infuzijeb
Subsequent maintenance therapy can be administered in one of two ways:
Naknadna terapija održavanja može se davati na jedan od sljedeća dva načina:
Subsequent testing should be conducted annually in children while they are receiving Revestive.
Kasnije, sve dok primaju Revestive, u djece treba provoditi testiranja jednom godišnje.
Subsequently the dose may be individually adjusted every 1 to 2 weeks to maintain the average neutrophil count between 1.5 x 109/l and 10 x 109/l.
Potom se doza može individualno prilagođivati svakih 1 do 2 tjedna kako bi se broj neutrofila održavao između 1,5 x 109/l i 10 x 109/l.
Subsequently the efficacy was confirmed in several field studies in cats and dogs, which were conducted in several different European geographical locations.
Naknadno je djelotvornost potvrđena u nekoliko terenskih studija na mačkama i psima, koje su provedene na nekoliko različitih zemljopisnih lokacija u Europi.
Subsequently, exenatide concentrations of approximately 300 pg/ml were maintained indicating that steady state was achieved.
Nakon toga su se koncentracije eksenatida održavale na otprilike 300 pg/ml, što ukazuje na to da je postignuto stanje dinamičke ravnoteže.
Subsequently, four years following the switch to Prevenar 13, the additional reduction in incidence of IPD due to the 7 serotypes in Prevenar ranged from 76% in children less than 2 years of age to 91% in children 5-14 years of age.
Posljedično, četiri godine nakon prelaska na Prevenar 13 dodatno smanjenje pojavnosti invazivne pneumokokne bolesti zbog 7 serotipova u Prevenaru bilo je od 76% u djece mlađe od 2 godine do 91% u djece od 5-14 godina.
Subsequently, prior to each Removab administration 500 ml sodium chloride 9 mg/ml (0.9%) solution for injection shall be infused to support distribution of the antibody in the abdominal cavity.
Posljedično, prije svake primjene Removaba primjenjuje se 500 ml otopine natrijevog klorida 9 mg/ml (0,9%) za injekciju kako bi se pospješila raspodjela protutijela u trbušnoj šupljini.
Subsequently, remove the needle from the vial.
Nakon toga izvucite iglu iz bočice.
Subsequently, the dose may be individually adjusted every 1-2 weeks to maintain the average neutrophil count between 1.5 x 109/L and 10 x 109/L.
Nakon toga, dozu je kod svakog pojedinog bolesnika moguće prilagođavati svaka 1-2 tjedna kako bi se prosječan broj neutrofila održao na vrijednostima između 1,5 x 109/l i 10 x 109/l.
Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Slijedom navedenog, nositelj odobrenja za stavljanje u promet lijeka će ta izvješća podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove.
Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Slijedom navedenog, nositelj odobrenja će ta izvješća podnositi u skladu s referentnim popisom datuma EU (EUDR popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove.
Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Slijedom navedenog, nositelj odobrenja će ta izvješća podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EC i objavljenim na europskom internetskom portalu za lijekove.
Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Slijedom navedenog, nositelj odobrenja će ta izvješća podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internet portalu za lijekove.
Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Slijedom navedenog, nositelj odobrenja će ta izvješća podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove
Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Slijedom navedenoga, nositelj odobrenja će ta izvješća podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove.
Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.>
Slijedom navedenog, nositelj odobrenja će ta izvješća podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove.
Subsequently, the Myocet infusion should be restarted in a different vein than that in which the extravasation has occurred.
Kasnije se infuzija Myoceta može ponovno pokrenuti, ali ne u veni na kojoj se dogodila ekstravazacija.
Subsequently, the patient will have an injection under the skin once a week.
Nakon toga bolesnik treba primati injekciju pod kožu jednom tjedno.
Subset analyses-adjuvant therapy in patients with node-negative breast cancer study (Intent-to-treat analysis)
Analiza podskupina – adjuvantno liječenje bolesnika s karcinomom dojke s negativnim limfnim čvorovima ("Intent-to-Treat" analiza)
Subset Analyses-Adjuvant Therapy in Patients with Node-negative Breast Cancer Study (Intent-to-Treat Analysis)
Analiza podskupina – adjuvantno liječenje bolesnika s karcinomom dojke s negativnim limfnim čvorovima (Intent-to-Treat analiza)
Substance dependence.
ovisnosti o drogama
Substance overdose
predoziranje
Substance-related radioactivity was largely excreted in urine (76%) and only to a low extent in faeces (1.5%) after 192 hours.
Radioaktivnost povezana s tvari obilato se izlučuje urinom (76%), a samo u maloj mjeri fecesom (1,5%) nakon 192 sata.
Substance-specific side effects:
Nuspojave specifične za djelatnu tvar:
Substances increasing the clearance of CHCs (diminished efficacy of CHCs by enzyme-induction),e.g.: Barbiturates, bosentan, carbamazepine, phenytoin, primidone, rifampicin, modafinil and HIV medication ritonavir, nevirapine and efavirenz and possibly also felbamate, griseofulvin, oxcarbazepine, topiramate and products containing the herbal remedy St. John's Wort (hypericum perforatum).
Barbiturati, bosentan, karbamazepin, fenitoin, primidon, rifampicin, modafinil i lijekovi za liječenje HIV-a ritonavir, nevirapin i efavirenz te također moguće felbamat, grizeofulvin, okskarbazepin, topiramat i lijekovi koji sadrže biljni pripravak gospinu travu (Hypericum perforatum).
Substances shown to be predominately excreted either via the active organic anionic pathway, or by glomerular filtration are unlikely to yield clinically significant interactions with lamivudine.
Mala je vjerojatnost da bi lijekovi koji se pretežno izlučuju aktivnim organskim anionskim putem ili glomerularnom filtracijom stupali u klinički značajne interakcije s lamivudinom.
Substances that are inducers of CYP3A or P-gp decrease the plasma concentrations of mirabegron.
Tvari koje induciraju CYP3A ili P-gp snižavaju koncentraciju mirabegrona u plazmi.
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St. John’s Wort) may significantly reduce exposure to Glivec, potentially increasing the risk of therapeutic failure.
Tvari koje induciraju djelovanje CYP3A4 (npr. deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital, fosfenitoin, primidon ili Hypericum perforatum, poznat također kao gospina trava) mogu značajno smanjiti izloženost Glivecu, čime se potencijalno povećava rizik od neuspjeha terapije.
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St. John’s Wort) may significantly reduce exposure to imatinib , potentially increasing the risk of therapeutic failure.
Tvari koje induciraju djelovanje CYP3A4 (npr. deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital, fosfenitoin, primidon ili Hypericum perforatum, poznat također kao gospina trava) mogu značajno smanjiti izloženost imatinibu, čime se potencijalno povećava rizik od neuspjeha terapije.
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St. John’s Wort) may significantly reduce exposure to imatinib , potentially increasing the risk of therapeutic failure.
Tvari koje induciraju djelovanje CYP3A4(npr. deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital, fosfenitoin, primidon ili Hypericum perforatum, poznat također kao gospina trava) mogu značajno smanjiti izloženost imatinibu, čime se potencijalno povećava rizik od neuspjeha terapije.
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St. John’s Wort) may significantly reduce exposure to imatinib, potentially increasing the risk of therapeutic failure.
Tvari koje induciraju djelovanje CYP3A4 (npr. deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital, fosfenitoin, primidon ili Hypericum perforatum, poznat također kao gospina trava) mogu značajno smanjiti izloženost imatinibu, čime se potencijalno povećava rizik od neuspjeha terapije.
Substances that are inducers of CYP3A4 activity may increase metabolism and decrease gefitinib plasma concentrations and thereby reduce the efficacy of gefitinib.
Tvari koje su induktori aktivnosti CYP3A4 mogu pojačati metabolizam i sniziti koncentracije gefitiniba u plazmi te time umanjiti djelotvornost gefitiniba.
Substances that are inducers of CYP3A4 or PgP may decrease everolimus blood concentrations by increasing metabolism or the efflux of everolimus from intestinal cells.
Tvari koje induciraju CYP3A4 ili PgP mogu sniziti koncentraciju everolimusa u krvi povećanjem metabolizma everolimusa ili njegovog izbacivanja iz stanica crijeva.
Substances that are inducers of CYP3A4, such as rifampicin, carbamazepine, barbiturates and St John’s wort (Hypericum perforatum) are likely to decrease the plasma concentrations of darifenacin.
Tvari koje induciraju CYP3A4, poput rifampicina, karbamazepina, barbiturata i Gospine trave (Hypericum perforatum) vjerojatno će smanjiti koncentraciju darifenacina u plazmi.
Substances that are substrates of CYP2B6 and CYP2C9 enzymes with narrow therapeutic range (e.g. warfarin, acenocoumarol, efavirenz, methadone) or BCRP substrates with narrow therapeutic range (e.g. methotrexate, mitoxantrone, irinotecan, topotecan) should be avoided.
Tvari koje su supstrati enzima CYP2B6 i CYP2C9 s uskim terapijskim rasponom (npr. varfarin, acenokumarol, efavirenz, metadon) ili supstrati BCRP-a s uskim terapijskim rasponom (npr. metotreksat, mitoksantron, irinotekan, topotekan) treba izbjegavati.
Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib concentrations.
Tvari koje inhibiraju aktivnost CYP3A4 izoenzima citokroma P450 (npr. inhibitori proteaze kao što su indinavir, lopinavir/ritonavir, ritonavir, sakvinavir, telaprevir, nelfinavir, boceprevir; azolni antimikotici uključujući ketokonazol, itrakonazol, posakonazol, vorikonazol; određeni makrolidi kao što su eritromicin, klaritromicin i telitromicin) mogle bi smanjiti metabolizam i povećati koncentracije imatiniba.
Substances that may cause methaemoglobinaemia include some antibiotics, local anaesthetics, nitrates in drinking water and pesticides.
Tvari koje mogu uzrokovati methemoglobinemiju uključuju određene antibiotike, lokalne anestetike, nitrate u vodi za piće i pesticide.
Substances that may enhance the blood-glucose-lowering activity and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors (MAOIs), pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics.
Tvari koje mogu pojačati učinak na snižavanje razine glukoze u krvi i povećati sklonost hipoglikemiji obuhvaćaju oralne antidijabetike, inhibitore angiotenzin konvertirajućeg enzima (ACE), dizopiramid, fibrate, fluoksetin, inhibitore monoaminooksidaze (MAO inhibitore), pentoksifilin, propoksifen, salicilate i sulfonamidske antibiotike.
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates, somatostatin anologues and sulphonamide antibiotics.
Tvari koje mogu pojačati učinak na snižavanje razine glukoze u krvi i povećati sklonost hipoglikemiji obuhvaćaju oralne antidijabetike, inhibitore angiotenzin konvertirajućeg enzima (ACE), dizopiramid, fibrate, fluoksetin, inhibitore monoaminooksidaze (MAO), pentoksifilin, propoksifen, salicilate, analoge somatostatina i sulfonamidske antibiotike.